<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="472">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 13, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00704405</url>
  </required_header>
  <id_info>
    <org_study_id>7009-009</org_study_id>
    <secondary_id>2007_659</secondary_id>
    <nct_id>NCT00704405</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Vaniprevir (MK-7009) With Pegylated Interferon (Peg-IFN) and Ribavirin (RBV) in Treatment-Experienced Hepatitis C Virus (HCV) Participants (MK-7009-009)</brief_title>
  <official_title>A Phase II Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of 4 Different Regimens of MK-7009 When Administered Concomitantly With Pegylated Interferon and Ribavirin in Treatment-Experienced Patients With Chronic Genotype 1 Hepatitis C Virus Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the safety, tolerability, and efficacy of 4 regimens of
      Vaniprevir + Peg-IFN and Ribavirin as compared to Placebo (PBO) + Peg-IFN/RBV. The primary
      hypotheses are that Vaniprevir is well tolerated, and that Vaniprevir 600 mg twice daily
      (b.i.d.) is superior to the control regimen for the percentage of non-cirrhotic (NC)
      participants achieving undetectable HCV ribonucleic acid (RNA) 24 weeks after the end of
      study therapy (SVR24).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Percentage of Participants Achieving SVR24 Following Treatment With Vaniprevir 600 mg b.i.d.</measure>
    <time_frame>Up to 72 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>The percentage of non-cirrhotic participants with undetectable Hepatits C virus (HCV) ribonucleic acid (RNA) 24 weeks after completing treatment was determined for each Vaniprevir 600 mg b.i.d. and control regimen. Results for Vaniprevir 300 mg are presented as a Secondary Outcome Measure.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Experiencing an Adverse Event (AE)</measure>
    <time_frame>Up to 73 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The number of non-cirrhotic participants experiencing AEs during the active Vaniprevir/PBO treatment and 14-day follow-up periods was monitored for each treatment regimen. An AE was defined as any unfavorable and unintended change in the structure (signs), function (symptoms), or chemistry (laboratory data) of the body temporally associated with any use of a Sponsor product, whether or not considered related to the use of the product.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Discontinuing From Study Treatment Due to AEs</measure>
    <time_frame>Up to 48 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The number of non-cirrhotic participants withdrawing from study treatment due to AEs during the active Vaniprevir/PBO treatment and 14-day follow-up periods was monitored for each treatment regimen.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving SVR24 Following Treatment With Vaniprevir 300 mg b.i.d.</measure>
    <time_frame>72 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>The percentage of non-cirrhotic participants treated with Vaniprevir 300 mg b.i.d. with undetectable HCV RNA 24 weeks after completing treatment was determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving cEVR</measure>
    <time_frame>Up to Week 60</time_frame>
    <safety_issue>No</safety_issue>
    <description>The percentage of non-cirrhotic participants with complete early viral response (cEVR; undetectable HCV RNA at Week 12) was determined for each Vaniprevir dose. Since each of the Vaniprevir 600 mg arms had the same treatment history at this point in the study, the data were pooled for analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving SVR24 After 24 Weeks of Vaniprevir 600 mg b.i.d.</measure>
    <time_frame>Week 48</time_frame>
    <safety_issue>No</safety_issue>
    <description>The percentage of participants achieving SVR24 after the 24-week Vaniprevir 600 mg b.i.d. regimen at Week 48 was compared to the control regimen.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">285</enrollment>
  <condition>Hepatitis C, Chronic</condition>
  <arm_group>
    <arm_group_label>24-wk Vaniprevir 600 mg + Peg-IFN/RBV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vaniprevir 600 mg (total daily dose) and RBV (1000 mg or 1200 mg total daily dose based on body weight) twice daily (b.i.d.) and Peg-IFN 180 mcg injection once weekly for 24 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>24-wk Vaniprevir 600 mg + 24-wk PBO + Peg-IFN/RBV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vaniprevir 600 mg (total daily dose) and RBV (1000 mg or 1200 mg total daily dose based on body weight) b.i.d. and Peg-IFN 180 mcg injection once weekly for 24 weeks, followed by PBO and RBV (1000 mg or 1200 mg total daily dose based on body weight) b.i.d. and Peg-IFN 180 mcg injection once weekly for an additional 24 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>48-wk Vaniprevir 300 mg + Peg-IFN/RBV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vaniprevir 300 mg (total daily dose, taken once daily [q.d.]) and RBV (1000 mg or 1200 mg total daily dose based on body weight) b.i.d. and Peg-IFN 180 mcg injection once weekly for 48 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>48-wk Vaniprevir 600 mg + Peg-IFN/RBV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vaniprevir 600 mg and RBV (1000 mg or 1200 mg based on body weight) b.i.d. and Peg-IFN 180 mcg injection once weekly for 48 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>48-wk PBO + Peg-IFN/RBV</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>PBO and RBV (1000 mg or 1200 mg based on body weight) b.i.d. and Peg-IFN 180 mcg injection once weekly for 48 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vaniprevir</intervention_name>
    <description>Participants took capsules containing 100 mg Vaniprevir twice daily (b.i.d.), three in the morning (300 mg and 600 mg regimens) and three in the evening (600 mg regimen only), orally, for 24 or 48 weeks.</description>
    <arm_group_label>24-wk Vaniprevir 600 mg + Peg-IFN/RBV</arm_group_label>
    <arm_group_label>24-wk Vaniprevir 600 mg + 24-wk PBO + Peg-IFN/RBV</arm_group_label>
    <arm_group_label>48-wk Vaniprevir 300 mg + Peg-IFN/RBV</arm_group_label>
    <arm_group_label>48-wk Vaniprevir 600 mg + Peg-IFN/RBV</arm_group_label>
    <other_name>MK-7009</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegylated Interferon (Peg-IFN)</intervention_name>
    <description>Participants used prefilled syringe containing 180 µg/0.5 mL Peg-IFN, for weekly subcutaneous injection, for 24 or 48 weeks</description>
    <arm_group_label>24-wk Vaniprevir 600 mg + Peg-IFN/RBV</arm_group_label>
    <arm_group_label>24-wk Vaniprevir 600 mg + 24-wk PBO + Peg-IFN/RBV</arm_group_label>
    <arm_group_label>48-wk Vaniprevir 300 mg + Peg-IFN/RBV</arm_group_label>
    <arm_group_label>48-wk Vaniprevir 600 mg + Peg-IFN/RBV</arm_group_label>
    <arm_group_label>48-wk PBO + Peg-IFN/RBV</arm_group_label>
    <other_name>PEGASYS™</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin (RBV)</intervention_name>
    <description>Participants took tablets containing 200 mg RBV, 5 or 6 tablet dosage based on the participant's weight, with food, for 24 or 48 weeks. The dose was 1000 mg for participants weighing &lt;=75 kg and 1200 mg for participants weighing &gt;75 kg.</description>
    <arm_group_label>24-wk Vaniprevir 600 mg + Peg-IFN/RBV</arm_group_label>
    <arm_group_label>24-wk Vaniprevir 600 mg + 24-wk PBO + Peg-IFN/RBV</arm_group_label>
    <arm_group_label>48-wk Vaniprevir 300 mg + Peg-IFN/RBV</arm_group_label>
    <arm_group_label>48-wk Vaniprevir 600 mg + Peg-IFN/RBV</arm_group_label>
    <arm_group_label>48-wk PBO + Peg-IFN/RBV</arm_group_label>
    <other_name>COPEGUS™</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (PBO)</intervention_name>
    <description>Participants took PBO capsules matching Vaniprevir capsules, three in the morning and three in the evening, for 24 or 48 weeks.</description>
    <arm_group_label>24-wk Vaniprevir 600 mg + 24-wk PBO + Peg-IFN/RBV</arm_group_label>
    <arm_group_label>48-wk PBO + Peg-IFN/RBV</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Has chronic HCV genotype 1 infection

          -  Is treatment-experienced

          -  For the non-cirrhotic population, has had a liver biopsy without evidence of
             cirrhosis and hepatocellular carcinoma; for the cirrhotic population, has had a liver
             biopsy with evidence of cirrhosis and without evidence of hepatocellular carcinoma.

        Exclusion criteria:

          -  Has not tolerated previous course peg-IFN and RBV

          -  Is unlikely to tolerate at least 24 weeks of continuous therapy with Peg-IFN and RBV

          -  Is co-infected with Human Immunodeficiency Virus (HIV) and/or hepatitis B

          -  Consumes excessive amounts of alcohol

          -  Has a history of drug or alcohol abuse

          -  If female, participant is pregnant or breastfeeding

          -  Has been in a clinical trail with an investigational drug in the last 30 days

          -  Has used IFN/Peg-IFN and RBV in the last 3 months
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>Czech Republic</country>
    <country>France</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Korea, Republic of</country>
    <country>Lithuania</country>
    <country>New Zealand</country>
    <country>Poland</country>
    <country>Puerto Rico</country>
    <country>Sweden</country>
    <country>Taiwan</country>
    <country>Thailand</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>Lawitz E, Rodriguez-Torres M, Stoehr A, Gane EJ, Serfaty L, Bhanja S, Barnard RJ, An D, Gress J, Hwang P, Mobashery N. A phase 2B study of MK-7009 (vaniprevir) in patients with genotype 1 HCV infection who have failed previous pegylated interferon and ribavirin treatment. J Hepatol. 2013 Jul;59(1):11-7. doi: 10.1016/j.jhep.2013.02.008. Epub 2013 Feb 21.</citation>
    <PMID>23439259</PMID>
  </results_reference>
  <results_reference>
    <citation>Rodriguez-Torres M, Stoehr A, Gane EJ, Serfaty L, Lawitz E, Zhou A, Bourque M, Bhanja S, Strizki J, Barnard RJ, Hwang PM, DiNubile MJ, Mobashery N. Combination of vaniprevir with peginterferon and ribavirin significantly increases the rate of SVR in treatment-experienced patients with chronic HCV genotype 1 infection and cirrhosis. Clin Gastroenterol Hepatol. 2014 Jun;12(6):1029-37.e5. doi: 10.1016/j.cgh.2013.09.067. Epub 2013 Oct 10.</citation>
    <PMID>24120953</PMID>
  </results_reference>
  <verification_date>September 2015</verification_date>
  <lastchanged_date>September 1, 2015</lastchanged_date>
  <firstreceived_date>June 23, 2008</firstreceived_date>
  <firstreceived_results_date>September 26, 2014</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hepatitis C</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Ribavirin</mesh_term>
  </intervention_browse>
  <!-- Results are available for this study                                           -->
</clinical_study>
